## Core Concept
The question tests the understanding of sympathomimetic agents, specifically their effects on bronchial smooth muscle. Sympathomimetic agents, also known as adrenergic agonists, mimic the effects of the sympathetic nervous system by stimulating adrenergic receptors. The primary receptors involved in bronchial smooth muscle relaxation are $beta_2$-adrenergic receptors.

## Why the Correct Answer is Right
The correct answer, , is known for its potent $beta_2$-adrenergic receptor agonist activity. This agent causes significant relaxation of bronchial smooth muscle, leading to bronchodilation. The $beta_2$-adrenergic receptors are coupled to Gs proteins, which activate adenylate cyclase, increasing intracellular cyclic AMP (cAMP) levels. Elevated cAMP levels lead to smooth muscle relaxation and, consequently, bronchodilation.

## Why Each Wrong Option is Incorrect
* **Option A:** is a non-selective $beta$-adrenergic agonist with more pronounced effects on $beta_1$-adrenergic receptors, which are primarily found in the heart. While it does have some effect on $beta_2$-adrenergic receptors, its cardiac effects are more prominent, making it less ideal as a bronchodilator.
* **Option B:** is an $alpha_1$-adrenergic receptor antagonist and has some $beta$-adrenergic blocking activity, which would not be beneficial for bronchodilation.
* **Option C:** has significant $alpha$-adrenergic agonist activity, leading to vasoconstriction and other effects not desirable for bronchodilation.

## Clinical Pearl / High-Yield Fact
A key point to remember is that $beta_2$-selective adrenergic agonists like are the preferred bronchodilators in asthma and COPD due to their targeted action on bronchial smooth muscle with fewer cardiac side effects compared to non-selective agents.

## Correct Answer Line
**Correct Answer: D. Salbutamol.**